共 50 条
- [41] Anatomical response to anti-vascular endothelial growth factor (anti-VEGF) in patients with diabetic macular edema (DME) and its potential "in vitro" prediction by using Induced Pluripotent Stem Cell (IPSC)-derived endothelial cells (ECs) INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
- [42] Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial JAMA OPHTHALMOLOGY, 2021, 139 (12) : 1285 - 1291
- [44] Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial JAMA OPHTHALMOLOGY, 2019, 137 (12) : 1389 - 1398
- [45] DESIGN AND RATIONALE OF A CLINICAL TRIAL TO MEASURE THE DEVELOPMENT OF GEOGRAPHIC ATROPHY IN PATIENTS UNDERGOING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION: THE RIVAL STUDY CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 113 - 113
- [48] Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048 KIDNEY CANCER, 2019, 3 (01) : 51 - 61
- [49] A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29 JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
- [50] Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)